Nuvation Bio Inc. (NYSE: NUVB) shares advanced 2.7% on Friday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $12 price target, implying a 73% upside from current levels based on discounted cash flow analysis.
Analyst Li Watsek described Nuvation as a low-risk, high-reward commercial-stage oncology story built on two targeted therapies, noting that the Street materially undervalues the size of both markets due to multi-year treatment duration. Watsek identified safusidenib as the mispriced prize within the portfolio.
Ibtrozi (taletrectinib), a next-generation ROS1 inhibitor launched in 2025, serves as the valuation floor. Cantor projects growing first-line use in ROS1+ non-small cell lung cancer, with multi-year therapy duration expected to drive U.S. peak sales of $965 million. Safusidenib, a differentiated IDH1 inhibitor in pivotal Phase 3 development for IDH1-mutant glioma, is noted to have a best-in-class profile de-risked by Servier’s approved Voranigo/INDIGO precedent, with approximately $1.9 billion in peak sales potential across the broadest development program in its class.
Nuvation’s current market capitalization stands at approximately $2.6 billion. The firm highlighted acquisitions of Turning Point, Mirati, Day One, and Chimerix as examples of substantial strategic interest for a commercial-targeted oncology company.
